QualityDipStocks / Health Care · Life Sciences Tools
Revvity RVTY
Outside our quality screen, so we don’t track its dips. It’s 5% below its 52-week high.
Outside our quality screen, trading well above our fair value estimate, 12% over its Market Value.
- Fair value est.
- $79.23−50%
- Market Value
- $140.28price +12%
- Off 52-wk high
- −5%
- Risk vs market
- Above marketbeta 1.20
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $157.00
- Fair value est.base case$79.23−49.5%
- 52-wk lowlowest close, 1 year$82.26−47.6%
- Market Valueavg paid since Aug 4$140.28−10.6%
- PriceFri Oct 30 close$157.00you are here
- 52-wk highhighest close, 1 year$165.78+5.6%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, RVTY’s free cash flow would need to grow about 15% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much RVTY moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 3.0× the S&P 500’s.
- Beta vs S&P 500
- 1.20
- Volatility
- 39% vs 13% SPY
- Correlation SPY
- 0.39
- Correlation QQQ
- 0.30
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
Cash returnsShare count down 5.0% in a year: $476M of buybacks over 12 months.
ProfitabilityGross margin widened to 60.1% in FY2023 from 55.8% in FY2021 (SEC filings).
ValuationPrice / book of 2.4×, below the 5.2× median for the 93 Health Care companies we cover.
Balance sheetDebt / equity of 0.4×, below the 0.7× median for the 67 Health Care companies we cover.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $79.23, 50% below the price.
ValuationP/E of 73.8× vs a 29.2× median for the 86 Health Care companies we cover.
ProfitabilityReturn on invested capital of 3%, below the 9.5% discount rate our DCF uses.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
ValuationTrades 11.9% above its Market Value of $140.28, the average price paid since the Aug 4 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Revvity in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Life Sciences Tools
All fundamentals
P/E 73.8 · FCF yield 3.2% · ROE 3%
Valuation
- P/E
- 73.8×Health Care median 29.2×
- Price / FCF
- 31.4×
- FCF yield
- 3.2%
- EV / EBITDA
- 25.6×
- Price / sales
- 6.02×
- Price / book
- 2.42×
- Market cap
- $17.5Bprice × diluted shares
- Enterprise value
- $19.7B
Growth
- Revenue, 12 months
- $2.9B
- Sales growth, 12 months
- +4.1%vs the 12 months before
- Sales growth, 3 yrs
- −4.8%/yrfrom FY2023
- Diluted EPS, 12 months
- $2.08
- EPS growth, last FY
- −5.9%
- Net income, 12 months
- $238M
- Net income growth
- −17%12 months vs before
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 12.3%
- Net margin
- 8.2%
- FCF margin
- 19.2%
- Return on equity
- 3%
- Return on invested capital
- 3%
Balance sheet
- Cash & short-term inv.
- $1.0B
- Total debt
- $3.2B
- Net cash
- −$2.2B
- Debt / equity
- 0.44×
- Interest coverage
- 3.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $558M
- FCF growth, 12 months
- +11%
- Dividend yield
- 0.18%$32M paid
- Payout ratio
- 13%
- Buybacks, 12 months
- $476M2.7% of market cap
- Share count, 1 year
- −5.0%diluted shares vs a year ago
- Stock-based comp
- $24M
Trailing 12 months to Jul 5, 2026; balance sheet at Jul 5, 2026. From Revvity’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $79.23 · MV $140.28 · FCF value $127.30
Assumes 3.0% growth for 5 years (revenue grew -4.8% a year FY23–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $5.00 a share (trailing 12 months to Jul 5, 2026), from the 10-Q filed Aug 11, 2026. Net debt $2.2B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 55 · 5 days −1.1%
The business
FCF $0.6B · Sales +1%
- Free cash flow, 12 months$0.6B
- Free-cash-flow yield3.2%
- Free-cash-flow margin21%
- Gross margin55%
- Operating margin17%
- Return on invested capital4%
- Return on equity3%
- Sales growth (latest quarter vs year-ago quarter)+1%
- Net debt / EBITDA2.6×
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$1.29
- Year-ago EPS$1.18
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
RVTY is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.